In vitro studies demonstrate that bone is degraded in an acidic environment due to chemical reactions and through effects on bone cells. Clinical evidence is insufficient to unequivocally resolve whether the diet net acid or base load bone affects breakdown in humans. Increasing dietary salt (sodium chloride, NaCl) mildly increases blood acidity in humans and in rats with increased sensitivity to the blood pressure effects of salt, whereas increased potassium (K) intake can decrease blood pressure. Blood pressure responses to NaCl or K may potentially be a marker for increased bone turnover or lower bone mineral density (BMD) in women at higher risk for osteoporosis and fracture. SUBJECTS/METHODS: We retrospectively analysed data from two data sets (California and NE Scotland) of postmenopausal women (n ¼ 266) enrolled in long-term randomized, placebo-controlled studies of the effects of administration of low-or high-dose dietary K alkali supplementation on bone turnover in relation to sodium or chloride excretion (a marker of dietary salt intake). Mean arterial pressure (MAP) was calculated from blood pressure measures, MAP was divided into tertiles and its influence on the effect of dietary NaCl and K alkali supplementation on deoxypyridinoline markers of bone resorption and BMD by DEXA was tested. Data was analysed for each data set separately and then combined. RESULTS: Percentage change in BMD after 24 months was less for California compared with North East Scotland (hip: À 0.6 ± 2.8% and À 1.5±2.4%, respectively (P ¼ 0.027); spine: À 0.5±3.4% and À 2.6±3.5%, (Po0.001). We found no effect of dietary alkali treatment on BMD change or bone resorption for either centre. Adjusting for the possible calcium-or potassium-lowering effects on blood pressure did not alter the results. CONCLUSIONS: Blood pressure responses to Na, Cl or K intake did not help predict a BMD response to diet alkali therapy.
INTRODUCTION
Dietary factors affecting osteoporosis Although many factors that affect bone mineral density (BMD) are known, they account for only half of the variability among subjects when assessing risks for osteoporosis. 1 Whether or not blood pressure responses to alterations in dietary acid (from table salt, NaCl) or base from potassium alkali salts is associated with osteoporosis is unclear. 2 Dietary acid and bone effects Increases in blood acid loads, marked by increased urinary acid excretion, increase calcium efflux from bone in in vitro; 3, 4 in human clinical trials, faecal calcium balance was not significantly changed, whereas urine calcium excretion increased, 5, 6 leading some authors to suggest that the calcium was coming from bone. 4, 6, 7 In rats and young men, very high dietary NaCl intake (above the usual diet levels) induce lower blood pH and bicarbonate and higher urinary net acid excretion 8, 9 and are associated with increased urinary markers of bone breakdown. 9 However, a recent cohort study that retrospectively measured net acids in frozen 2-h urine specimens did not show an association with BMD or fractures 10 and a 2-year intervention study demonstrated no improvement in BMD in subjects treated with dietary alkali. 11 Salt intake and bone effects Dietary salt may affect bone metabolism via a number of mechanisms. In healthy men, increasing Na intake from 10 to 1500 mmol (0.5-65 g/day) on a fixed calcium intake increased the filtered load of calcium and fractional calcium excretion (Po0.001). 12, 13 Studies suggest that urinary Ca decreases by 0.5 to 1.5 mmol (20-60 mg/day) for every 100 mmol (2300 mg) decrease in sodium ingested. 14, 15 In the DASH-Na diet, low salt intake was associated with decreased urinary Ca excretion and significantly reduced bone turnover markers; calcium balance, a more robust indicator of bone health, was not measured. 16 Increases in either intravenous or dietary Na intake are linked to increases in hormones such as parathyroid hormone (PTH) 17 that are known to affect bone turnover. Increases in dietary chloride intake is associated with decreasing blood pH and serum bicarbonate (HCO 3 ), 18 leading to higher blood acid levels. Together, increased Na and Cl intake are associated with increased urine calcium excretion and increased blood acid levels, respectively, within the range of normal, and may potentially contribute directly or indirectly to bone turnover.
Salt intake, blood pressure, nitric oxide (NO) and bone NaCl intake can increase blood pressure in some individuals 19, 20, 21 and potassium intake can lower blood pressure. 22 Blood pressure effects in cardiovascular disease have been well studied; 22, 23 more recently, factors important in cardiovascular disease are now also being seen as possibly affecting bone health. 24, 25 Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of endothelial NO synthase; increases in ADMA inhibit NO-related vasodilation, leading to increased blood pressure. 26 Fang et al. 27 in cross-over studies in normotensive rural Chinese demonstrated significantly higher mean blood pressures and ADMA levels in 13 salt-sensitive (SS) normotensive subjects on a high salt diet compared with a low salt diet (Po0.05 and o0.01, respectively) and compared with 47 salt-resistant (SR) subjects on either salt diet. Sharma et al. 28 in cross-over studies showed that SS humans on a high salt diet also have significantly lower arterial blood pH (Po0.0001) and HCO 3 (Po0.0001) levels than SR subjects. In our preliminary cross-over studies, significant increases in urinary Ca excretion (corrected for creatinine excretion) associated with increases in ADMA occurred in SS subjects on a high NaCl diet, but not in SR subjects (R 2 ¼ 0.47, P ¼ 0.02 vs R 2 ¼ 0.03, P ¼ 0.57, respectively) and not in the SS subjects on a low salt diet. 29 Recent studies have shown that giving NO mimetics may improve bone density. NO has been shown to prevent bone breakdown in ovariectomized rats and women. 30 A small study comparing isosorbide dinitrate 60 mg daily to alendronate 70 mg weekly by Nabhan and Rabie 31 demonstrated equivalent increases in BMD in postmenopausal women after 1 year of treatment. More recently, an analysis of subjects from the Canadian Multicentre Osteoporosis Study showed significant positive associations between nitrate users and higher BMD. 32 Based on the evidence that sensitivity to salt as reflected by higher blood pressures for a given salt intake affects ADMA and may differentially affect bone metabolism, 29 we retrospectively tested correlations between blood pressure, NaCl and K alkali salt intake and changes in bone markers or BMD in 266 postmenopausal (predominantly Caucasian) women who had been subjects in osteoporosis studies in California and Scotland and randomized to either placebo, potassium alkali salts or fruits and vegetables (latter Scotland only).
SUBJECTS AND METHODS

North East (NE) Scotland
Subjects. Subjects for this retrospective study were a subset of postmenopausal women living in the Aberdeen area who provided 24-h urine samples during a dietary intervention trial. 11 Exclusion criteria for the original study, which was registered at http://www.controlled-trials.com as ISRCTN86186352, were the lowest 10% of estimated dietary acidity (NEAP calculated from the food frequency questionnaires), 33 and any condition or medication that would affect bone metabolism and potassium-sparing diuretics. Women taking other types of diuretics or hypertension tablets and women on thyroxine treatment provided their thyroid function was stable (as assessed by free T4 and TSH) and their dose had not changed in the year before study entry were included in the study. Ethical permission was obtained from Grampian Research Ethics Committee (02/0053).
Randomisation and Intervention. The subjects were randomized to one of the four groups: placebo, 'low' dose (18.5 mEq) or 'high' dose (55.5 mEq) potassium citrate, or fruit and vegetables (usual daily intake of fruit and vegetables plus 300 g). The women did not receive Ca or vitamin D supplements.
Dietary intake and anthropometric assessments. The European Prospective Study into Cancer (EPIC) food diary was completed for 4 days before randomisation and at 1 year 34, 35, 36 and analysed using 'Windiets' (Robert Gordon University, Aberdeen, UK). Women were weighed 6-monthly on balance scales (Seca, Hamburg, Germany) and height was measured at baseline and 2 years with a stadiometer (Holtain Ltd, Crymych, UK). Blood pressure was measured with an automatic sphygmomanometer (Omron 705CP; Omron Healthcare Ltd, Milton Keynes, UK) and measured in the same arm at each visit after the patient was settled and before venipuncture was performed.
Markers of bone health. Urine free deoxypyridinoline cross-links (fDPD) were measured in 2 h early morning fasted urine samples at baseline, 3, 6, 12, 18 and 24 months. Creatinine (Cr) and Na were measured with standard automated techniques on a P module (Roche, Lewes, UK), and the results are expressed as fDPD/Cr (nmol/mmol). The inter-assay CV for the marker method was o5.5% across the working range. The method used is a modification of the HPLC technique published previously utilising mass spectrometry (MS) detection of DPD. 37 BMD was measured at the spine and hip at baseline and at 2 years by the same radiographer using a Lunar Prodigy DXA scanner (GE Medical Systems Inc., Madison, WI, USA). Daily phantom measurements were performed. Short-term precision was estimated using duplicate measurements from seven postmenopausal women (from a separate study). CV was 0.5% for spine (L2-L4) and 0.6% for total hip.
Compliance measures. Compliance was estimated at each visit by capsule count for the potassium citrate and placebo groups, and by dietary reporting and biomarkers (plasma vitamin C, whole-cell folate) for the diet arm. 38 Twenty-four-hour urine study. The women (n ¼ 70 at study start, n ¼ 57 at study end) collected 24-h urine samples at baseline, 3, 6, 12, 18 and 24 months for measurement of urinary pH and concentrations of potassium (K), Na, Ca, phosphate (PO 4 ), urea and Cr.
California
Subjects. Subjects were recruited from the San Francisco Bay area. The study was approved by the Institutional Review Board and all subjects signed informed consent. Exclusion criteria were: renal or cardiac disease, parathyroid disease, previous bisphosphonate treatment, vertebral fracture by history of an X-ray, BMDp À 2.5 on DEXA, o5 years past menopause, hormone replacement therapy in the last 6 months or currently taking oral corticosteroids or potassium-sparing diuretics. We included women taking other types of diuretics or hypertension tablets and women on thyroxine treatment provided their thyroid function was within the normal range and medication doses unchanged in the last year. This study was started before clinical trial registration was required. Some of the data from this study has been published. 39 Randomisation and intervention. The subjects were randomly assigned to one of four groups; one group received placebo pills and the other three arms were given active tablets containing 30, 60 or 90 mEq of potassium bicarbonate (KHCO 3 ). One-third of all subjects were randomized to placebo, one-third to 60 mmol of K and the remaining one-third to either 30 or 90 mmol of K. All subjects received Ca supplements (calcium carbonate) if necessary to ensure a dietary intake of Ca of at least 1200 mg/ day (30 mmol/day) and a vitamin D supplement of 400 IU. We followed subjects at month 1 and then every 3 months for up to 36 months with repeated blood samples and 24-h urine samples.
Dietary intake and anthropometric assessments. Dietary intake of Ca and protein were estimated by questionnaires. 40 Women were weighed (Scaletronix, White Plains, NY, USA) and height measured with a stadiometer (Perspective Enterprises, Portage, MI, USA) at each visit associated with a DEXA study. Blood pressure was measured with an automatic sphygmomanometer (DinaMap, GE Healthcare/GE Medical Systems Inc., USA) and measured in the same arm at each visit after the patient was settled and before venipuncture was performed.
Markers of bone health. Urine fDPD was measured in 2-h early morning fasted urine samples at baseline and every 3 months (Nichols Institute San Juan Capistrano, CA, USA). Cr was measured by colorimetric assay (COBAS, Roche) and the results are expressed as fDPD/Cr (nmol/mmol).
BMD was measured at the spine and both hips at baseline and yearly using a Lunar Prodigy DXA scanner (GE Medical Systems Inc.). Daily quality assurance measurements were performed.
Compliance measures. Compliance was judged by capsule counts every 3 months and 24-h urinary K excretion.
Twenty-four-hour urine study. Twenty-four-hour urine samples for K, Na, Ca, Cl, PO 4 and Cr were obtained twice at baseline and then every 3 months. Samples for Na, K and Cl were measured by ion-selective electrode and those for Ca, PO4 and Cr were measured by colorimetric assay at Quest Diagnostics (San Jose, CA, USA).
All subjects
Blood pressure determinations. For each individual, the mean arterial pressure (MAP) was calculated from the equation: MAP ¼ diastolic blood pressure þ 1/3(systolic À diastolic blood pressures). The women were divided into tertiles of low, medium or high MAP at the baseline visit. MAP was also divided by 24-h urinary Na excretion as a measure of blood pressure response to salt intake; MAP/Na. Change in MAP was calculated as the average of all MAPs on treatment minus the average of all MAPs before treatment.
PRAL and NAE calculations. For the Aberdeen cohort, we estimated urine PRAL from the formula:
Diet net acid load was estimated as PRAL þ OA production, where PRAL was calculated from the estimated dietary intakes and OA production using the body surface area method:
Also for that group, we estimated diet net acid load from the formula using estimates of dietary protein and potassium:
For the California cohort, we estimated urine PRAL from the formula:
Diet net acid load was estimated using the Frassetto formula above, modified so that we used urine K as an estimate of diet K. We had insufficient dietary data to calculate dietary PRAL.
Statistical analysis. All statistical analyses were carried out using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Independent t-test for the continuous variables (with log transformation of the variable if required) and chi-squared test for categorical variables were used to test for differences between the populations. Repeated measures analysis of variance (ANOVA) were used to analyse changes in K excretion (as a measure of treatment compliance) and fDPD/Cr (bone resorption) over time. One-way ANOVA was used to analyse the 2-year change in BMD between treatment groups. Linear regression analysis was used to determine predictors of blood pressure responses to salt that could be potential confounders in the relationship between BMD change and salt intake. Analysis of covariance (ANCOVA) then allowed for the adjustment of these potential confounders (body mass index (BMI), 24-h urinary Ca excretion and 24-h urinary K excretion). Similarly ANOVA and ANCOVA were used to explore the cross-sectional relationship between tertiles of MAP/Na and baseline BMD. When the data from both centres were combined, the 18.5 mmol dose from NE Scotland was combined with the 30 mmol dose of the California centre to give a low K salt group, and the 55.5 mmol dose from NE Scotland was combined with the 60 mmol dose from California to give a high K salt group. Both centres contributed to the combined placebo group.
RESULTS
A total of 266 postmenopausal women attended the baseline visit. Compared with the Scottish women (n ¼ 70), the Californian women (n ¼ 196) were marginally older, taller; had lower BMI but they had similar biochemical profiles (Table 1) . Overall, the experimental intervention was completed by 209 women (78.5%) over 2 years and the withdrawal rate was similar across the treatment groups (Figure 1) . Figure 2 gives an estimate of treatment compliance for both centres, as measured by 24-h urinary K excretion. Overall compliance was good with significant increases in K excretion from baseline according to the dose of K salt (repeated measures ANOVA Po0.001) for the combined centres (California Po0.001, NE Scotland P ¼ 0.004), although there was a temporary decrease at 6 months for the 90-mEq group.
MAP in mm Hg at baseline for the combined centres were 82.3±5.2 (low), 94.3±3.3 (medium) and 110.3±8.5 (high) (oneway ANOVA Po0.0001). Of the 266, 20 (8%) were on blood pressure medications. A sensitivity analysis with and without this group was unchanged. For the Californian women, the numbers of women defined as having low, medium and high blood pressures in relation to salt intake were 66, 65 and 65, respectively. The corresponding numbers for the Scottish women were 22, 25 and 23 ( Table 2) . At baseline, the subjects who had the lowest blood pressure in relation to Na intake had the highest urinary Na excretion (one-way ANOVA Po0.0001) and the highest urinary K and Ca excretion (Po0.01, Po0.02, respectively). Linear regression analysis of all subjects showed that 24-h urinary K and Ca excretion, and BMI were significant predictors of MAP/Na accounting for 8.5%, 4.2% and 1.3% of the total variation, respectively (full data not shown). These variables were then included as confounders in the following ANCOVA analysis. The California group also had 24-h urine chloride measurements evaluated; there was no association with MAP (P ¼ 0.08). There was a significant inverse correlation between change in MAP and K intake with treatment (r ¼ À 0.20, Po0.05).
The overall percentage bone loss ± s.e.m. for NE Scotland was À 1.5±2.4% for the hip, À 2.6±3.5% for LS (lumbar spine); and for California it was À 0.6±2.8% for the hip and 0.5%±3.4% for LS. The differences between centres was significant (P ¼ 0.027 hip, Po0.001 spine). We found no difference in 2-year percentage change in BMD, either at the hip or spine in relation to K salt treatment, for either centre. The response did not differ according to blood pressure in relation to sodium intake (Figures 3a-d) . Adjustment for confounders did not change the relationship. Further, combining the data from both centres to maximise power (with 18.5 mmol and 30 mmol contributing to 'low-dose K salt' (n ¼ 49), 55.5 mmol and 60 mmol to the 'high-dose K salt' treatment (n ¼ 76) and a combined placebo group (n ¼ 95)) did not change the outcome (ANCOVA adjusting for urinary K and Ca excretion and BMI. For hip: P ¼ 0.119 for low MAP/Na, P ¼ 0.203 for medium MAP/ Na and P ¼ 0.997 for high MAP/Na groups. For LS, P ¼ 0.959 for low MAP/Na, P ¼ 0.117 for medium MAP/Na and P ¼ 0.923 for high MAP/Na groups).
For all women, regardless of the blood pressures responses to Na, 3-monthly urinary measures of bone resorption did not differ according to dose of K salt (repeated measures ANOVA: NE Scotland P ¼ 0.858, California P ¼ 0.762) ( Table 3) . When testing the cross-sectional relationship between MAP/Na and bone health: for NE Scotland baseline, BMD was observed to be higher in the lowest category of MAP/Na compared with the other categories, but this was not statistically significant (P ¼ 0.061); for the California centre, there was no relationship (P ¼ 0.165); and adjustments for confounders did not change the outcome for either centre (Table 2) . Further, if the two centres were combined, there was no statistically significant association with or without adjustments for confounders, including study centre (data not shown).
Data for the dietary estimates of net acid production and excretion at baseline are shown in Table 4 . The estimates between the two cohorts for the diet net acid production and urinary PRAL are quite similar, and similar to other estimates of dietary net acid excretion for Western diets. Completed study visits n=65 Figure 1 . Details of study recruitment and randomisation for the NE Scotland and California. K citrate, potassium citrate; KHCO 3 , potassium bicarbonate.
DISCUSSION
Contrary to our hypothesis that blood pressure responses to NaCl intake (as measured by MAP and MAP/24-h urinary Na excretion) could help predict bone response to alkali therapy, in this population of predominantly healthy Caucasian postmenopausal women, no differences in BMD at the hip or spine or differences in urinary fDPD excretion were seen between treatment groups. The women were enrolled for at least 2 years in studies designed to investigate the effects of dietary alkali intake on bone health. The bone loss observed for NE Scotland for the 24-h urine subset was similar to that already reported for the full data set. 11 This is the first time the Californian data relating to bone health have been shown. The percentage bone loss was less compared with NE Scotland, which may be because the Californian women were more than 5 years past the menopause.
Earlier studies evaluating the potential effects of high alkali diets on BMD and fracture risk have had conflicting results. Some observational studies suggest a role for acid-base balance on fractures 42 and others do not. 10 Intervention studies of 1 year or less suggest a positive effect 43, 44, 45 on markers of bone turnover. Whereas one 2-year placebo-controlled trial did not find an effect of K citrate on BMD, 11 a more recent study found increases in BMD and bone strength. 46 These findings support the latter investigators' earlier study that reported treatment with K citrate attenuated 1-year bone loss compared with K chloride. 43 A number of meta-analyses have questioned the hypothesis that the diet net acid load reduces bone mass. 10, 47, 48, 49 Mean estimated dietary NEAP is in the order of þ 40 mEq/day, whereas estimated urinary PRAL is low. If these women were eating generally healthy diets, although dietary acidity was positive, it was perhaps insufficiently acidic enough (as indicated by the negative urinary PRAL) so that the additional alkaline-generating potassium salts did not benefit BMD.
Although our data fail to show that moderately high alkali diets are beneficial to bone health in younger healthy postmenopausal Caucasian women, other subgroups of subjects might respond to alkali therapy, for example, older subjects with more age-related renal dysfunction 41 or those with metabolic syndrome. Presence of risk factors for the metabolic syndrome is associated with both higher blood pressures with higher salt intake 50 and higher fracture risk. 51 Metabolic syndrome has been associated with decreased production of NO, and NaCl has been shown to dose dependently decrease endothelial NO synthase activity in endothelial cells. 52 NO synthases have been demonstrated in both osteoclasts and osteoblasts. 53, 54 NO may be the mediator by which oestrogen or androgen therapy improves BMD. Nitrate use is associated higher BMD 32 and prevents bone loss in postmenopausal women. 30, 31 The subjects in our study had relatively few risk factors for metabolic syndrome. Although the women in the Scottish cohort tended to be heavier than the California cohort, and we do not have information on lipid profile, only a small percentage of the women were taking medications for blood pressure or had abnormal fasting glucose measures.
Another explanation for the null finding is that the effect size of dietary acid and salt is small compared with the effect size of other factors that affect bone metabolism. In the Study of Osteoporotic Fractures, 42 the observational analyses had to be corrected for age, energy intake, total Ca intake (dietary Ca plus supplements), total protein intake, weight, current oestrogen use, physical activity, smoking status and alcohol intake before associations with potential acid intake could be detected. The subjects in the Study of Osteoporotic Fractures were a decade older than our subjects and had age-related decline in renal function. In contrast, the women in our intervention studies were apparently healthy.
In population studies, higher K intake is associated with lower blood pressures. 22, 55 Among our subjects, those whose blood pressures were the lowest at baseline, independent of Na intake had the highest urinary K excretion, and increasing K intake with treatment lowered blood pressure. Meta-analyses of calcium supplementation trials have also shown a slight lowering of blood pressures, 56 but adjusting for baseline calcium excretion did not change our results.
There were some limitations of our study. First, there is no agreed upon definition of what constitutes a blood pressure response to salt. 57 In typical salt-sensitivity metabolic studies, subjects' blood pressures are measured on a low salt diet and then on a high salt diet, with sensitivity to salt being defined by how much the subjects blood pressure increased, usually 3-5 mm Hg. As this was a retrospective analysis; this was not possible. However, average MAP differences between our three tertiles were 12-16 mm Hg and significantly different from each other. Second, we were unable to analyse some bone markers, such as C-telopeptide (CTX) or propeptide type 1 procollagen (P1NP), which were not done in the California study; recent literature suggests that CTX and P1NP are more precise bone markers than urine fDPD. 58 Although the Scottish study followed 260 women, only 70 of them had 24-h urine studies collected, and urine chloride was not done. Third, the California women received a calcium and vitamin D supplement, whereas the Scottish women did not. However, analyses of the two studies separately did not , low MAP/Na ¼ 0.55 ± 0.097, medium MAP/Na ¼ 0.81 ± 0.078 and high MAP/Na ¼ 1.45 ± 0.50 mm Hg/mmol Na) and P ¼ 0.167 for low MAP/Na, P ¼ 0.803 for medium MAP/Na and P ¼ 0.743 for high MAP/Na groups (one-way ANOVA)). After adjustment for urinary potassium, calcium and BMI, P ¼ 0.299, P ¼ 0.748, and P ¼ 0.715, respectively for low, medium and high SS groups (ANCOVA). Overall mean % change in hip BMD À 1.7± 3.2% low MAP/Na, À 1.4±2.2% medium MAP/Na and À 1.4±1.5% high MAP/Na. (b) Mean (±s.e.m.) % change in left hip BMD over 24 months for the Californian subjects with K alkali treatment according to tertile of salt sensitivity (n ¼ 66, 65, 65 for low, medium and high MAP/Na, respectively, ((±s.d.), low MAP/Na ¼ 0.58±0.097, medium MAP/Na ¼ 0.85 ± 0.083 and high MAP/Na ¼ 1.40 ± 0.51 mm Hg/mmol Na) and P ¼ 0.423 for low MAP/Na, P ¼ 0.078 for medium MAP/ Na and P ¼ 0.887 for high MAP/Na groups for mean change in hip BMD (one-way ANOVA)). After adjustment for urinary potassium, calcium and BMI, P ¼ 0.385, P ¼ 0.147 and P ¼ 0.971, respectively, for low, medium and high MAP/Na groups (ANCOVA). Overall mean % hip BMD À 0.2 ± 2.4% low MAP/Na, À 1.4 ± 3.0% medium MAP/Na and À 0.5 ± 2.7% high MAP/Na. (c) Mean % change in lumbar spine BMD over 24 months (±s.e.m.) for the NE Scottish subjects (MAP/Na details as for panel (a)) and P ¼ 0.113 for low MAP/Na, P ¼ 0.730 for medium MAP/Na and P ¼ 0.586 for high MAP/Na groups (one-way ANOVA). After adjustment for urinary potassium, calcium and BMI, P ¼ 0.171, P ¼ 0.849 and P ¼ 0.840, respectively, for low, medium and high MAP/Na groups (ANCOVA). Overall mean % LS BMD À 3.3±2.9% low MAP/Na, À 1.5±3.4% medium MAP/Na and À 3.3 ± 4.1% high MAP/Na. (d) Mean ( ± s.e.m.) % change in lumbar spine BMD over 24 months for the Californian subjects (MAP/Na details as for panel (b)) and P ¼ 0.311 for low MAP/Na, P ¼ 0.152 for medium MAP/Na and P ¼ 0.870 for high MAP/Na groups for mean change in lumbar spine BMD (one-way ANOVA). After adjustment for urinary potassium, calcium and BMI, P ¼ 0.318, P ¼ 0.363 and P ¼ 0.883, respectively, for low, medium and high MAP/Na groups (ANCOVA). Overall mean % LS BMD À 0.8±2.7% low MAP/Na, À 0.3±3.3% medium MAP/Na and À 0.5±4.7% high MAP/Na. yield different results. Finally, the DXA studies were done on two different machines without phantoms used to correlate the differences between machines. However, both DXA scanners were the same model and made by the same manufacturer. It is also possible that restoring bone loss with potassium and alkali requires a larger dietary net base load than we achieved in our studies, which may have not been sufficient to replete the skeletal base reservoir. A study that gradually increased the dose of K alkali to achieve diet net base loads of 75-100 mEq/day for 2 years might have revealed a beneficial effect on bone modulable by the degree of blood pressure disturbance and NaCl intake.
In conclusion, adjustment for salt sensitivity did not alter the trials findings on no effect of alkali treatment on bone outcomes. Abbreviations: NAE, net acid excretion; NEAP, net acid production; PRAL, potential renal acid load.
